- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Genelux GAAP EPS of -$0.19 beats by $0.01 | 1 | Seeking Alpha | ||
| 29.10. | Guggenheim sees upside in Genelux shares, targets $8 as pivotal cancer trial progresses | 1 | Investing.com | ||
| 22.10. | Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer | 136 | GlobeNewswire (Europe) | - VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small... ► Artikel lesen | |
| 09.10. | Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 04.10. | Genelux announces executive departure | 2 | Investing.com | ||
| 03.10. | Genelux kündigt Abgang einer Führungskraft an | - | Investing.com Deutsch | ||
| 03.10. | GENELUX Corp - 8-K, Current Report | 2 | SEC Filings | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 14.09. | Genelux corp insider sells over $170k in company stock | 1 | Investing.com | ||
| 13.09. | Genelux director Tyree James L sells shares worth over $4,400 | 2 | Investing.com | ||
| 12.09. | Genelux corp insider sells over $196k in company stock | 2 | Investing.com | ||
| 31.08. | Genelux Corp insider sells over $550k in company stock | 3 | Investing.com | ||
| 29.08. | Genelux started at buy by Roth MKM ahead of Olvi-Vec readouts | 5 | Seeking Alpha | ||
| 15.08. | Genelux GAAP EPS of -$0.22 | 1 | Seeking Alpha | ||
| 14.08. | Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates | 247 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter... ► Artikel lesen | |
| 13.08. | Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds | 2 | Insider Monkey | ||
| 01.08. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024 | 1 | GlobeNewswire (USA) | ||
| 05.06. | GENELUX Corp - 8-K, Current Report | - | SEC Filings | ||
| 31.05. | Unveiling 4 Analyst Insights On Genelux | 1 | Benzinga.com | ||
| 24.05. | Pre-market Movers: Akanda, Verastem, Tian Ruixiang, Merus N.V., Genelux | 777 | AFX News | MOUNTAIN VIEW (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.50 A.M. ET).In the Green Akanda Corp. (AKAN) is up over 125% at $5.40.
Tian... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| INFLARX | 1,993 | +2,47 % | InflaRx N.V.: InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| REDHILL BIOPHARMA | 6,370 | -6,32 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,200 | +2,48 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| CURIS | 3,600 | +2,86 % | Curis Inc Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Curis Inc (CRIS) released Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's bottom line totaled -$10.09... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,534 | -3,92 % | BioXcel Therapeutics-Aktie erreicht 52-Wochen-Tief bei 0,50 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 5,815 | -3,73 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| COHERUS | 1,100 | +4,91 % | Coherus BioSciences, Inc.: Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update | - Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter - - UDENYCA labeling and packaging production resuming at third-party contract manufacturing... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,130 | -1,43 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ESPERION | 2,297 | +0,22 % | Esperion Therapeutics, Inc.: Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 | ||
| ADAPTIMMUNE THERAPEUTICS | 0,615 | -3,15 % | Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints | ||
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| FIBROGEN | 0,319 | -3,54 % | FibroGen, Inc.: FibroGen Reports Third Quarter 2024 Financial Results | Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with... ► Artikel lesen | |
| KARYOPHARM | 0,793 | +7,37 % | Karyopharm appoints new chief accounting officer |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,465 Euro und damit -1,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.
